This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Moses, J. W. Articles by Stone, G. W. Search for Related Content PubMed PubMed Citation Articles by Moses, J. W. Articles by Stone, G. W.

Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes

Analysis from the TAXUS-IV trial

Jeffrey W. Moses, MD, FACC^_*,, Roxana Mehran, MD, FACC^_*,, Eugenia Nikolsky, MD^_*,, John M. Lasala, MD, FACC^,1, Woodrow Corey, MD, FACC, Glenn Albin, MD, FACC^||, Cary Hirsch, MD, FACC^¶, Martin B. Leon, MD, FACC^_*,, Mary E. Russell, MD, FACC^#,2, Stephen G. Ellis, MD, FACC^_**,1 and Gregg W. Stone, MD, FACC^_*,,1,_*

^_* Columbia University Medical Center, New York, New York
The Cardiovascular Research Foundation, New York, New York
Washington University School of Medicine, St. Louis, Missouri
Community Hospitals of Indianapolis, Indianapolis, Indiana
^|| Saint Mary’s Hospital, Duluth, Minnesota
^¶ Valley Hospital, Ridgewood, New Jersey
^# Boston Scientific Corp., Natick, Massachusetts
^_** Cleveland Clinic Foundation, Cleveland, Ohio.

View larger version (17K): [in a new window]   Figure 1 Cumulative risk of major adverse cardiac events in patients with acute coronary syndromes treated with paclitaxel-eluting stents versus bare-metal stents.

View larger version (24K): [in a new window]   Figure 2 One-year clinical outcomes in patients with unstable and stable ischemic syndromes treated with paclitaxel-eluting versus bare-metal stents. MACE = major adverse cardiac events; TVR = target vessel revascularization.